https://biobran.org Sun, 23 Aug 2026 13:44:34 +0000 en-US hourly 1 https://wordpress.org/?v=7.1 https://biobran.org/wp-content/uploads/2026/08/cropped-FaviBB-1-32x32.webp https://biobran.org 32 32 https://biobran.org/dieatary-supplementation-with-biobran-mgn-3-increases-innate-resistance-and-reduces-the-incidence-of-influenza-like-illnesses-s-in-elderly-subjects-a-randomized-double-blind-placebo-controlled-pilo/ Mon, 16 Aug 2021 19:45:00 +0000 https://biobran.org/?p=759 Abstract: Influenza-like illness (ILI) remains a major cause of severe mortality and morbidity in the elderly. Aging is associated with a decreased ability to sense pathogens and mount effective innate and adaptive immune responses, thus mandating the development of protective nutraceuticals. Biobran/MGN-3, an arabinoxylan from rice bran, has potent anti-aging and immunomodulatory effects, suggesting that it may be effective against ILI. The objective of the current study was to investigate the effect of Biobran/MGN-3 on ILI incidence, natural killer (NK) cell activity, and the expressions of RIG-1 (retinoic acid-inducible gene 1), MDA5 (melanoma differentiation-associated protein 5), and their downstream signaling genes ISG-15 (interferon-stimulated genes 15) and MX1 (myxovirus (influenza) resistance 1, interferon-inducible). A double-blind, placebo-controlled clinical trial included eighty healthy older adults over 55 years old, 40 males and 40 females, who received either a placebo or Biobran/MGN-3 (500 mg/day) for 3 months during known ILI seasonality (peak incidence) in Egypt. The incidence of ILI was confirmed clinically according to the WHO case definition criteria. Hematological, hepatic, and renal parameters were assessed in all subjects, while the activity of NK and NKT (natural killer T) cells was assessed in six randomly chosen subjects in each group by the degranulation assay. The effect of Biobran/MGN-3 on RIG-1 and MDA5, as well as downstream ISG15 and MX1, was assessed in BEAS-2B pulmonary epithelial cells using flow cytometry. The incidence rate and incidence density of ILI in the Biobran/MGN-3 group were 5.0% and 0.57 cases per 1000 person-days, respectively, compared to 22.5% and 2.95 cases per 1000 person-days in the placebo group. Furthermore, Biobran/MGN-3 ingestion significantly enhanced NK activity compared to the basal levels and to the placebo group. In addition, Biobran/MGN-3 significantly upregulated the expression levels of RIG-1, MDA5, ISG15, and MX1 in the human pulmonary epithelial BEAS-2B cell lines. No side effects were observed. Taken together, Biobran/MGN-3 supplementation enhanced the innate immune response of elderly subjects by upregulating the NK activity associated with reduction of ILI incidence. It also upregulated the intracellular RIG-1, MDA5, ISG15, and MX1 expression in pulmonary epithelial tissue cultures. Biobran/MGN-3 could be a novel agent with prophylactic effects against a wide spectrum of respiratory viral infections that warrants further investigation.

]]> https://biobran.org/clinical-cancer-strategy-clinical-review/ Mon, 16 Aug 2021 19:44:00 +0000 https://biobran.org/?p=756 This clinical cancer strategy incorporates advancements in cancer treatment based on a multi-approach to the disease that includes targeting apoptosis, immune cell activation, angiogenesis, restoration of cellular respiration, inhibition of inflammatory mediators, not mentioning some secondary factors such as intoxication, disturbed microbiome, and nervous disorders. I believe that a real breakthrough in cancer needs to promote immune system enhancement and activate apoptosis. These two important mechanisms of approaching cancer, principally through the clinical application of the P53 tumor suppressor gene and other apoptotic players that for the past 15 years have been included in my cancer strategy as a diagnostic, prognosis, and follow up treatment. P53 mutation or mutated P53 protein remains the essential factor when it comes to treating cancer either from conventional therapy or an alternative approach or in combination.

]]>